Gilead Sciences, Inc. (NASDAQ:GILD) Director John Francis Cogan sold 5,833 shares of the firm’s stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $80.09, for a total transaction of $467,164.97. Following the completion of the transaction, the director now directly owns 58,452 shares of the company’s stock, valued at approximately $4,681,420.68. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
John Francis Cogan also recently made the following trade(s):
- On Monday, March 12th, John Francis Cogan sold 5,833 shares of Gilead Sciences stock. The shares were sold at an average price of $80.93, for a total transaction of $472,064.69.
Shares of Gilead Sciences, Inc. (GILD) opened at $75.57 on Friday. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $89.54. The company has a debt-to-equity ratio of 1.53, a quick ratio of 2.67 and a current ratio of 2.74. The company has a market cap of $100,199.45, a price-to-earnings ratio of 8.96, a P/E/G ratio of -1.76 and a beta of 1.24.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be paid a dividend of $0.57 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a yield of 3.02%. The ex-dividend date of this dividend is Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 65.52%.
Several brokerages have commented on GILD. Barclays reissued an “overweight” rating and issued a $95.00 price target (up previously from $90.00) on shares of Gilead Sciences in a research report on Tuesday, March 6th. BidaskClub cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, March 3rd. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. Royal Bank of Canada reissued a “buy” rating and issued a $94.00 price target on shares of Gilead Sciences in a research report on Friday, February 23rd. Finally, Leerink Swann reissued a “market perform” rating and issued a $80.00 price target (down previously from $83.00) on shares of Gilead Sciences in a research report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $88.61.
Large investors have recently made changes to their positions in the stock. Welch Investments LLC acquired a new position in Gilead Sciences in the third quarter valued at $108,000. Wealthcare Advisory Partners LLC acquired a new position in Gilead Sciences in the third quarter valued at $133,000. Certified Advisory Corp acquired a new position in Gilead Sciences in the fourth quarter valued at $133,000. Horan Capital Advisors LLC. acquired a new position in Gilead Sciences in the third quarter valued at $144,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new position in Gilead Sciences in the second quarter valued at $147,000. Hedge funds and other institutional investors own 77.83% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://weekherald.com/2018/03/23/insider-selling-gilead-sciences-inc-gild-director-sells-467164-97-in-stock.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.